Comparative Pharmacology
Head-to-head clinical analysis: UROPLUS DS versus UROPLUS SS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UROPLUS DS versus UROPLUS SS.
UROPLUS DS vs UROPLUS SS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
UROPLUS DS is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim inhibits dihydrofolate reductase, blocking the reduction of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade disrupts folic acid synthesis, leading to bacterial growth inhibition.
Uroplus SS contains sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid (PABA) for dihydropteroate synthase. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. The sequential blockade of folic acid metabolism produces bactericidal activity.
UROPLUS DS (methenamine mandelate 1 g + sodium acid phosphate 500 mg) oral: 1 tablet twice daily.
4 grams orally once daily as a single dose or in divided doses for 10 to 14 days for urinary tract infections.
None Documented
None Documented
Terminal elimination half-life is 11-13 hours in adults with normal renal function; prolonged to 16-20 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 25 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is 18–24 hours, allowing once-daily dosing; steady-state achieved in 3–5 days.
Renal excretion of unchanged drug accounts for approximately 40-50% of elimination; hepatic metabolism (primarily via CYP3A4) and subsequent biliary/fecal excretion constitute the remainder with about 20-30% recovered in feces as metabolites.
Renal: 70–80% as unchanged drug; fecal: 10–20% via biliary elimination; minimal hepatic metabolism.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic